- Home
- TNXP
as 07-26-2024 4:00pm EST
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CHATHAM |
| Market Cap: | 18.2M | IPO Year: | N/A |
| Target Price: | $53.50 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -132.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.46 - $36.80 | Next Earning Date: | 08-08-2024 |
| Revenue: | $10,250,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 82.72% | Revenue Growth (next year): | 34.20% |
Latest Tonix Pharmaceuticals Holding Corp. News
TNXP Breaking Stock News: Dive into TNXP Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Tonix Pharmaceuticals Gets FDA Fast Track Label For Tonmya; Shares Rise
GlobeNewswire
2 days ago
Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia
MT Newswires
2 days ago
Tonix Pharmaceuticals Signs Deal with US Defense Department to Develop Antiviral Drugs
ACCESSWIRE
3 days ago
Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
Zacks Small Cap Research
8 days ago
TNXP: High Interest in Tonmya Seen in Initial Findings from Market Opportunity Analysis…
ACCESSWIRE
10 days ago
Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
GlobeNewswire
16 days ago
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
MT Newswires
17 days ago
Tonix Pharmaceuticals Prices $4 Million Public Offering; Shares Plunge
Compare TNXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TNXP Tonix Pharmaceuticals Holding Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.